XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

Rhea-AI Summary

XOMA Royalty Corporation (NASDAQ: XOMA) announced its participation in two upcoming investor conferences. At the H.C. Wainwright 1st Annual Royalty Company Virtual Conference on May 13, 2025, CEO Owen Hughes and CIO Brad Sitko will lead multiple sessions. Hughes will participate in a fireside chat at 2:30 PM ET and join a panel on royalty model pros and cons at 4:00 PM ET. Sitko will discuss development-stage companies and royalty platforms at 5:00 PM ET.

Additionally, XOMA's business development team will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York on May 20, 2025. The presentations will be accessible through XOMA's investor relations website.

EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at the H.C. Wainwright 1^st Annual Royalty Company Virtual Conference being held May 13, 2025.

Mr. Hughes and Mr. Sitko will participate in a fireside chat at 2:30 PM ET.  Mr. Hughes will join the “Pros and Cons of Royalty Model – Especially in Current Financing Environment” panel discussion at 4:00 PM ET.  Mr. Sitko will participate in the “Development-Stage Companies – Where do Royalty and Tech Platforms Play Fit?” panel at 5:00 PM ET.  Registration for the conference can be accessed by visiting https://ct.to/wD4ms7s.  XOMA Royalty’s presentations can be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.  

In addition, members of XOMA Royalty’s business development team will attend the H.C. Wainwright 3^rd Annual BioConnect Investor Conference being held on May 20, 2025, in New York, NY.

About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.

XOMA Investor Contact Juliane Snowden             XOMA Royalty   +1 646-438-9754             juliane.snowden@xoma.com

XOMA Media Contact Kathy Vincent KV Consulting & Management kathy@kathyvincent.com

FAQ

What conferences will XOMA Royalty Corporation (XOMA) attend in May 2025?

XOMA will attend the H.C. Wainwright 1st Annual Royalty Company Virtual Conference on May 13 and the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025.

Who are the XOMA executives presenting at the H.C. Wainwright Royalty Conference?

CEO Owen Hughes and CIO Brad Sitko will be presenting at the conference.

What topics will XOMA's executives discuss at the H.C. Wainwright Royalty Conference?

They will participate in a fireside chat, discuss pros and cons of the royalty model in the current financing environment, and address development-stage companies and royalty platforms.

How can investors access XOMA's presentations from the conference?

Investors can access the presentations through XOMA's investor relations website at www.xoma.com.